Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Singh, Tej Pratap ^a,d   Schön, Michael P ^b   Wallbrecht, Katrin ^b   Gruber Wackernagel, Alexandra ^a   Wang, Xiao Jing ^c   Wolf, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF COLORADO   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 9; INTERLEUKIN 9 RECEPTOR; MESSENGER RNA; PROTEIN ANTIBODY; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; EPIDERMIS HYPERPLASIA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAST CELL; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; SKIN INFILTRATE; TH17 CELL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-9; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PSORIASIS; SKIN; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA1;

MUS; MUS MUSCULUS;

EID: 84872421516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051752     Document Type: Article

References (52)

1. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, et al. (2008) IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 9: 1347-1355.
2. Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, et al. (2010) TGF-beta induces IL-9 production from human Th17 cells. J Immunol 185: 46-54.
3. Goswami R, Kaplan MH, (2011) A brief history of IL-9. J Immunol 186: 3283-3288.
4. Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C, (2010) Regulation of IL-9 expression by IL-25 signaling. Nat Immunol 11: 250-256.
5. Steenwinckel V, Louahed J, Orabona C, Huaux F, Warnier G, et al. (2007) IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 178: 3244-3251.
6. Hauber HP, Bergeron C, Hamid Q, (2004) IL-9 in allergic inflammation. Int Arch Allergy Immunol 134: 79-87.
7. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, et al. (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997-1002.
8. Cheng G, Arima M, Honda K, Hirata H, Eda F, et al. (2002) Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 166: 409-416.
9. Chang HC, Sehra S, Goswami R, Yao W, Yu Q, et al. (2010) The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 11: 527-534.
10. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, et al. (2010) Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33: 192-202.
11. Noelle RJ, Nowak EC, (2010) Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 10: 683-687.
12. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, et al. (2009) IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 206: 1653-1660.
13. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK, (2009) Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183: 7169-7177.
14. Li H, Nourbakhsh B, Ciric B, Zhang GX, Rostami A, (2010) Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol 185: 4095-4100.
15. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, et al. (2009) IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A 106: 12885-12890.
16. Friberg C, Bjorck K, Nilsson S, Inerot A, Wahlstrom J, et al. (2006) Analysis of chromosome 5q31-32 and psoriasis: confirmation of a susceptibility locus but no association with SNPs within SLC22A4 and SLC22A5. J Invest Dermatol 126: 998-1002.
17. Schön MP, Boehncke WH, (2005) Psoriasis. N Engl J Med 352: 1899-1912.
18. Pittelkow MR, (2005) Psoriasis: more than skin deep. Nat Med 11: 17-18.
19. Nickoloff BJ, Wrone-Smith T, (1997) Animal models of psoriasis. Nat Med 3: 475-476.
20. Nickoloff BJ, (2007) Cracking the cytokine code in psoriasis. Nat Med 13: 242-244.
21. Li AG, Wang D, Feng XH, Wang XJ, (2004) Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 23: 1770-1781.
22. Singh TP, Huettner B, Koefeler H, Mayer G, Bambach I, et al. (2011) Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-beta 1 transgenic mice. Am J Pathol 178: 699-708.
23. Singh TP, Schon MP, Wallbrecht K, Michaelis K, Rinner B, et al. (2010) 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 184: 7257-7267.
24. Zibert JR, Wallbrecht K, Schon M, Mir LM, Jacobsen GK, et al. (2011) Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. J Clin Invest 121: 410-421.
25. Han G, Li F, Singh TP, Wolf P, Wang XJ, (2012) The pro-inflammatory role of TGFbeta1: a paradox? Int J Biol Sci 8: 228-235.
26. Singh TP, Schon MP, Wallbrecht K, Wolf P, (2012) 8-Methoxypsoralen plus UVA treatment increases the proportion of CLA+ CD25+ CD4+ T cells in lymph nodes of K5.hTGFbeta1 transgenic mice. Exp Dermatol 21: 228-230.
27. Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, et al. (2011) Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One 6: e18266.
28. Schmitt E, Germann T, Goedert S, Hoehn P, Huels C, et al. (1994) IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol 153: 3989-3996.
29. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, et al. (2010) Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 163: 1282-1290.
30. Mabuchi T, Takekoshi T, Hwang ST, (2011) Epidermal CCR6+ gammadelta T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol 187: 5026-5031.
31. Cai Y, Shen X, Ding C, Qi C, Li K, et al. (2011) Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 35: 596-610.
32. Eller K, Wolf D, Huber JM, Metz M, Mayer G, et al. (2010) IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 186: 83-91.
33. Abdelilah S, Latifa K, Esra N, Cameron L, Bouchaib L, et al. (2001) Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J Immunol 166: 2768-2774.
34. Kearley J, Erjefalt JS, Andersson C, Benjamin E, Jones CP, et al. (2010) IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med.
35. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, et al. (2003) IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 170: 3461-3467.
36. Wiener Z, Falus A, Toth S, (2004) IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice. Cytokine 26: 122-130.
37. Stassen M, Muller C, Arnold M, Hultner L, Klein-Hessling S, et al. (2001) IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol 166: 4391-4398.
38. Asarch A, Barak O, Loo DS, Gottlieb AB, (2008) Th17 cells: A new paradigm for cutaneous inflammation. J Dermatol Treatment 19: 259-266.
39. Chua RA, Arbiser JL, (2009) The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity 42: 574-579.
40. Halin C, Detmar M, (2008) Chapter 1. Inflammation, angiogenesis, and lymphangiogenesis. Methods Enzymol 445: 1-25.
41. Heidenreich R, Röcken M, Ghoreschi K, (2009) Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 90: 232-248.
42. Simonetti O, Lucarini G, Goteri G, Zizzi A, Biagini G, et al. (2006) VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: Results of an immunohistochemical study. Int J Immunopathol Pharmacol 19: 751-760.
43. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A 107: 4448-4453.
44. Akman A, Yilmaz E, Mutlu H, Ozdogan M, (2009) Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 34: e202-204.
45. Crawshaw AA, Griffiths CE, Young HS, (2012) Investigational VEGF antagonists for psoriasis. Expert Opin Investig Drugs 21: 33-43.
46. Inzinger M, Heschl B, Weger W, Hofer A, Legat FJ, et al. (2011) Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol 165: 640-645.
47. Inzinger M, Weger W, Salmhofer W, Wolf P, (2012) Differential Response of Chronic Plaque Psoriasis to Briakinumab vs. Ustekinumab. Acta Derm Venereol. 92: 357-358.
48. Wolf P, Weger W, Legat FJ, Posch-Fabian T, Gruber-Wackernagel A, et al. (2012) Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol 166: 147-153.
49. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, et al. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366: 1190-1199.
50. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, et al. (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366: 1181-1189.
51. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, et al. (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. Online Nov 11. doi:10.1038/ng.2467.
52. Costanzo A, Chimenti MS, Botti E, Caruso R, Sarra M, et al. (2010) IL-21 in the pathogenesis and treatment of skin diseases. J Dermatol Sci 60: 61-66.